Deep‐Penetrating Triple‐Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models
Authors:
Abstract
Chemoradiotherapy (CRT) is the most accepted treatment for locally advanced pancreatic ductal adenocarcinoma (PDAC) and can significantly improve the R0 resection rate. However, there are few long‐term survivors after CRT. Although some polymer nanoparticles have shown potential in alleviating the dose‐limiting toxicity and assisting the chemotherapy of PDAC, there are few efficient nanosensitizers (NS) available for CRT of this malignancy, especially in the context of its hypoxic nature. Herein, based on the biological features of PDAC, a γ‐glutamyl transpeptidase (GGT)/glutathione (GSH)/hypoxia triple‐responsive prodrug NS to overcome the biological barrier and microenvironmental limitations confronted by CRT in PDAC is developed. Due to triple‐responsiveness, deep tumor penetration, GSH/hypoxia‐responsive drug release/activation, and hypoxia‐induced chemoradio‐sensitization can be simultaneously achieved with this NS. As a result, tumor shrinkage after CRT with this NS can be observed in both subcutaneous and orthotopic PDAC models, foreshadowing its potential in clinical neoadjuvant CRT.Keywords
Funding Information
- National Natural Science Foundation of China (52033001, 51973014, 21774008, 51390481)
- Fundamental Research Funds for the Central Universities (XK1701, XK1802‐8, BUCTRC201912)
This publication has 81 references indexed in Scilit:
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trialThe Lancet Oncology, 2013
- Reduced Glutathione: A Radioprotector or a Modulator of DNA-Repair Activity?Nutrients, 2013
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized TrialJournal of Clinical Oncology, 2013
- Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer OncogeneID4Science Translational Medicine, 2012
- Photoswitchable Nanoparticles for Triggered Tissue Penetration and Drug DeliveryJournal of the American Chemical Society, 2012
- Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patientsRadiation Oncology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- The role of radiotherapy in multimodal treatment of pancreatic carcinomaRadiation Oncology, 2010
- Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lungNature Biotechnology, 2007
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005